title: Wavefront-optimized surface ablation with the Allegretto Wave Eye-Q excimer laser platform: 12-month visual and refractive results.
abstract: OBJECTIVE
  To evaluate the wavefront-optimized algorithm of the Allegretto Wave Eye-Q (Wavelight AG) 400-Hz excimer laser platform.
  
  
  METHODS
  Three hundred three eyes of 303 patients treated with advanced surface ablation were evaluated prospectively. Topical mitomycin C (MMC) was used when ablation was ≥80 μm. Efficacy, safety, and predictability at 12 months were quantified with subjective refraction, visual acuity (logMAR), and slit-lamp examination.
  
  
  RESULTS
  Mean postoperative uncorrected distance visual acuity (UDVA) was 20/20.5 (0.01±0.05 logMAR). Postoperative UDVA was equal or better than preoperative corrected distance visual acuity (CDVA) in 94.7% of eyes. Efficacy index was 1.05. Corrected distance visual acuity was maintained (93.7%) or improved (5.9%) in 99.6% of treated eyes. No patient lost ≥2 lines. Safety index was 1.05. Haze at 12 months was grade ≤0.5 in 98% of treated eyes and grade ≤1 in 100% of treated eyes. Mean postoperative manifest refraction spherical equivalent (MRSE) was -0.03±0.15 diopters (D). Postoperative MRSE was within ±0.50 D in 99% of eyes. Overcorrection was documented in 0.66% and undercorrection in 0.33% of eyes.
  
  
  CONCLUSIONS
  The wavefront-optimized algorithm of the Allegretto Wave Eye-Q excimer laser platform showed good efficacy, safety, and predictability in advanced surface ablation, with or without MMC intraoperative use.
authors.affiliation: Department of Ophthalmology, University of Padova, Italy.
authors.forename: Catia
authors.initials: C
authors.lastname: Gambato
authors.forename: Anton Giulio
authors.initials: AG
authors.lastname: Catania
authors.forename: Stela
authors.initials: S
authors.lastname: Vujosevic
authors.forename: Edoardo
authors.initials: E
authors.lastname: Midena
mesh_terms: D000328:Adult; D000465:Algorithms; D000477:Alkylating Agents / Q000008:administration & dosage; D001251:Astigmatism / Q000503:physiopathology / Q000601:surgery*; D003315:Cornea / Q000503:physiopathology / Q000601:surgery*; D005260:Female; D006801:Humans; D054018:Lasers, Excimer / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D009216:Myopia / Q000503:physiopathology / Q000601:surgery*; D011446:Prospective Studies; D012029:Refraction, Ocular / Q000502:physiology*; D016896:Treatment Outcome; D014792:Visual Acuity / Q000502:physiology*; D055815:Young Adult
chemical_list: D000477:Alkylating Agents; D016685:Mitomycin